Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement
Apr 15, 06:54 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therapeutics and Galera Therapeutics enter a $350 million merger agreement, and industry leaders explore a new standard for copay program excellence.